WAT Waters Corporation

Waters Expands CORTECS Analytical Column Portfolio

Waters Corporation (NYSE:WAT) today expanded its CORTECS® Columns product line with the introduction of two new chemistries: Waters® CORTECS T3 and CORTECS Shield RP18. These new CORTECS column chemistries allow scientists to obtain more information per analysis and reduce the cost of analyzing complex samples such as biomarkers, natural products, counterfeit cosmetics, synthetic cannabinoids, veterinary drugs, drinking water, and vitamins.

This Smart News Release features multimedia. View the full release here: http://www.businesswire.com/news/home/20161110005272/en/

Waters Corporation introduces two new column chemistries: Waters® CORTECS T3 and CORTECS Shield RP18 ...

Waters Corporation introduces two new column chemistries: Waters® CORTECS T3 and CORTECS Shield RP18 allowing scientists to obtain more information per analysis and reduce the cost of analyzing complex samples. (Photo: Business Wire)

“Today’s scientists want more tools for improving the resolution, speed, selectivity, and sensitivity of their UPLC, UHPLC, and HPLC separations,” said Doug McCabe, Director of Product Management - Consumables Group. “CORTECS Columns deliver the batch-to-batch reproducibility, robustness, and quality that customers have come to expect from Waters.”

When used with an ultra-low dispersion ACQUITY UPLC® instrument platform, the CORTECS UPLC 1.6 micron particle columns are designed to deliver approximately 40% greater increase in separations efficiency when compared to fully porous particles of an equivalent particle size. The highly-efficient CORTECS 2.7 micron particle columns are for use on both the ACQUITY Arc™ UHPLC system and the Waters Alliance® HPLC system and operate at lower backpressures allowing for the use of longer column lengths to improve resolution or shorten analysis times and increase throughput.

The CORTECS T3 and CORTECS Shield RP18 chemistries compliment the currently available CORTECS C18+, C18, C8, Phenyl, and HILIC chemistries. All CORTECS chemistries are fully scalable between the 1.6 micron and 2.7 micron particle sizes. The CORTECS T3 and CORTECS Shield RP18 chemistries are offered in 48 unique column configurations and are immediately available for shipping worldwide.

It’s All in the Chemistry

With different particle characteristics and innovative charged surface modifications, CORTECS Columns are suitable for use in a wide variety of applications.

CORTECS T3 columns provide balanced retention for polar and non-polar molecules when run under reversed-phase LC conditions. The increased pore diameter (120Å vs. 90Å) along with the lower C18 ligand density and proprietary end capping enables the CORTECS T3 chemistry to operate in 100% aqueous mobile phase without the fear of the phase dewetting.

Shield RP18 columns utilize an embedded carbamate functional group into the alkyl ligand which provides alternative selectivity for basic and polyphenolic compounds when compared to typically bonded C18 phases. The embedded polar carbamate groups act as hydrogen bond acceptors, and provide unique selectivity especially for basic and polyphenolic compounds.

For more information: www.waters.com/cortecs

About Waters Corporation (www.waters.com)

Waters Corporation (NYSE:WAT) develops and manufactures advanced analytical and material science technologies for laboratory dependent organizations. For more than 50 years, the company has pioneered a connected portfolio of separations science, laboratory information management, mass spectrometry and thermal analysis systems.

Waters, ACQUITY, ACQUITY UPLC, ACQUITY Arc, Alliance, UltraPerformance LC, UPLC and CORTECS are trademarks of Waters Corporation.

EN
10/11/2016

Underlying

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Waters Corporation

Dave Nicoski ... (+2)
  • Dave Nicoski
  • Ross LaDuke

Vermilion Compass: Weekly Equity Strategy

Back to Near-Term Bullish on SPX and QQQ We downgraded our near-term outlook on the S&P 500 (SPX) and Nasdaq 100 (QQQ) to neutral last week (11/19/25 Compass), after being bullish since our 4/22/25 Compass, while maintaining our intermediate-term bullish outlook (as of our 5/14/25 Compass). Crucial support levels of 6480-6520 on SPX and $580-$583 on QQQ held last week, and we are right back to being near-term bullish as long as these support levels continue to hold. Just know that SPX could see...

Dave Nicoski ... (+2)
  • Dave Nicoski
  • Ross LaDuke

Vermilion Compass: Weekly Equity Strategy

6550-6569 S&P 500 Support Holding For Now After 5.5-months, the S&P 500 (SPX) has now failed to break and stay below the its 20-day MA. However, 6569 has been our level that needs to break in order for us to have confidence that a pullback has begun; SPX made a low of 6551 on Friday (less than 20 points or 0.3% from our 6569 level), meaning it was not a decisive breakdown (in time or price). As a result, our near-term bullish outlook since our 4/22/25 Compass remains intact, and it will stay t...

Waters Corp: 1 director

A director at Waters Corp bought 1,000 shares at 332.900USD and the significance rating of the trade was 87/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the last two years clearly s...

Dave Nicoski ... (+2)
  • Dave Nicoski
  • Ross LaDuke

Vermilion Short Shots: Technically Vulnerable Stocks

Short Shots is a collection of technically vulnerable charts culled from the Negative Inflecting and Toppy columns within our Weekly Compass report or from various technical screening processes. The charts contained in this report have developed concerning technical patterns that suggest further price deterioration is likely. For these reasons Short Shots can also be a great source of ideas for investors interested in short-selling candidates.

ResearchPool Subscriptions

Get the most out of your insights

Get in touch